Login to Your Account

Durect examination: FDA wants under way phase III to add new active control

By Randy Osborne
Staff Writer

Friday, April 8, 2016

Durect Corp. said Friday it was still “working through the logistics” of changes wanted by the FDA in the already-started phase III trial called Persist with Posimir, an extended-release form of bupivacaine delivered via depot for pain after surgery.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription